Brief: Vor Bio Doses First AML Patient with VCAR33
17/01/2024 21:02
Jan 17 (Reuters) - Vor Biopharma Inc VOR.O :
* VOR BIO DOSES FIRST AML PATIENT WITH VCAR33 (ALLO) AND
PROVIDES
CORPORATE UPDATE
* VOR BIOPHARMA INC: CASH RUNWAY EXTENDED INTO SECOND HALF
OF 2025
WITH CLINICAL TRIALS ON TRACK
* VOR BIOPHARMA INC - INITIAL DATA FROM VBP301 IS EXPECTED
IN
SECOND HALF OF 2024
Source text for Eikon: ID:nGNX5nWKsD
Further company coverage: VOR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vor Biopharma
See all newsBrief: Telitacicept Demonstrates Durable Preservation Of Kidney Function Through Two Years In Phase 3 Teligan Trial In Iga Nephropathy
Vor Bio says its experimental drug slowed loss of kidney function in late-stage study
U.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning